Citadel Advisors
CLSD

Citadel Advisors’s Clearside Biomedical CLSD Stock Holding History

Citadel Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-393
Closed -$5.42K – 12801
2025
Q1 		$5.42K Sell
393
-400
-50% -$5.74K ﹤0.01% 13818
2024
Q4 		$11.3K Sell
793
-814
-51% -$13.4K ﹤0.01% 13557
2024
Q3 		$30.6K Buy
1,607
+434
+37% +$7.41K ﹤0.01% 12413
2024
Q2 		$22.9K Buy
1,173
+606
+107% +$11.7K ﹤0.01% 12516
2024
Q1 		$13K Hold
567
– – ﹤0.01% 13321
2023
Q4 		$9.95K Hold
567
– – ﹤0.01% 13130
2023
Q3 		$7.39K Hold
567
– – ﹤0.01% 13261
2023
Q2 		$9.52K Sell
567
-580
-51% -$9.98K ﹤0.01% 13254
2023
Q1 		$17.9K Sell
1,147
-733
-39% -$14.2K ﹤0.01% 13144
2022
Q4 		$31.6K Sell
1,880
-500
-21% -$9.01K ﹤0.01% 12675
2022
Q3 		$40K Sell
2,380
-553
-19% -$12.1K ﹤0.01% 11757
2022
Q2 		$65K Buy
2,933
+1,160
+65% +$28.2K ﹤0.01% 11760
2022
Q1 		$61K Sell
1,773
-3,574
-67% -$107K ﹤0.01% 12663
2021
Q4 		$221K Sell
5,347
-880
-14% -$57K ﹤0.01% 11636
2021
Q3 		$560K Buy
6,227
+2,314
+59% +$204K ﹤0.01% 9591
2021
Q2 		$286K Sell
3,913
-940
-19% -$43.7K ﹤0.01% 11382
2021
Q1 		$180K Buy
4,853
+2,713
+127% +$136K ﹤0.01% 11827
2020
Q4 		$88K Buy
2,140
+1,447
+209% +$37.5K ﹤0.01% 10293
2020
Q3 		$16K Buy
+693
New +$17.9K ﹤0.01% 9894
2020
Q1 		– Sell
-1,093
Closed -$48K – 9635
2019
Q4 		$48K Buy
+1,093
New +$23K ﹤0.01% 8765
2019
Q3 		– Sell
-1,007
Closed -$15K – 9210
2019
Q2 		$15K Buy
+1,007
New +$18K ﹤0.01% 8982
2019
Q1 		– Sell
-2,233
Closed -$36K – 9312
2018
Q4 		$36K Buy
+2,233
New +$105K ﹤0.01% 8563
2018
Q3 		– Sell
-907
Closed -$145K – 9249
2018
Q2 		$145K Buy
+907
New +$153K ﹤0.01% 8086

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's CLSD Position: Q4 2024 in Review

Citadel Advisors sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 4,774 shares — an estimated $78.5K sold.

Citadel Advisors first reported a position in CLSD in Q2 2017 and held it in 24 quarters. The position peaked at $1.91M in Q1 2018. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • Citadel Advisors reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 4,774 Clearside Biomedical shares in Q4 2024, an estimated $78.5K.
  • Citadel Advisors first reported a position in Clearside Biomedical in Q2 2017 and held it in 24 quarters.
  • Citadel Advisors's Clearside Biomedical position peaked at $1.91M in Q1 2018.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.